Speakers
Nagy Habib
Head of Research and Development
MiNa Therapeutics
Post-Conference Focus Day
Thursday April 7, 2022
2:00 pm | Pre-Clinical and Clinical Delivery to Myeloid Cells and CNS
Dong Wei
Chief Executive Officer
EdiGene
Day Two
Wednesday April 6, 2022
9:10 am | RNA Therapeutics with LEAPER 2.0: Initial Proof of Concept in Preclinical Models including Human Primary Cells, Mice and Nonhuman Primates
Zhen Li
Chief Executive Officer
ADARx
Day Two
Wednesday April 6, 2022
9:40 am | An ADARx Pre-Clinical Model of RNA Editing Therapeutics
Ranjan Batra
Vice President Research and Development
Locanabio
Day Two
Wednesday April 6, 2022
8:40 am | RNA Targeting Gene Therapy for Neuromuscular Disease
Joey Verdi
Co-founder and Chief Scientific Officer
Hepione Therapeutics
Post-Conference Focus Day
Thursday April 7, 2022
1:30 pm | A New Tool for the Delivery of RNA Therapeutics to Specific Target Cells
Paul Vogel
Postdoctoral Researcher
Stanford University
Michael Breen
Assistant Professor
Icahn School of Medicine at Mount Sinai
Day One
Tuesday April 5, 2022
8:40 am | Fundamentals of RNA Editing in the Central Nervous System
Shizuka Uchida
Professor & Co-Director
Aalborg University
Day Two
Wednesday April 6, 2022
4:10 pm | A-I RNA Editing in the Cardiovascular System and Disease
Emanuela Felley- Bosco
Group Leader
University of Zürich
Day Two
Wednesday April 6, 2022
3:40 pm | RNA Editing in Mesothelioma
Erez Levanon
Professor
Bar Ilan University
Day One
Tuesday April 5, 2022
1:40 pm | Global Quantification Exposes Abundant Low-Level Off-Target Activity by Base Editors
Eli Eisenberg
Professor
Tel Aviv University
Day One
Tuesday April 5, 2022
9:10 am | Quantitative Analysis of the Endogenous Editome to Guide Base- Editing Development
Alan Herbert
Founder and Head of Discovery
InsideOutBio
Day Two
Wednesday April 6, 2022
4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing
1:30 pm | Flipons, Editing and Cancer
Amy Lancaster
Principal Scientist, Research
Korro Bio
Day One
Tuesday April 5, 2022
11:10 am | Platform Optimization to Enable Therapeutic Development of ADARMediated RNA Editing
Nina Papavasilou
Professor, Division Head
DKFZ German Cancer Research Centre
Day Two
Wednesday April 6, 2022
4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing
3:10 pm | ADARs, APOEBECS, and tumours: RNA Editing and Disease Manifestations
Robert Goodnow
Vice President Medicinal Chemistry
Stoke Therapeutics
Day One
Tuesday April 5, 2022
11:40 am | Panel Discussion: Chemical Modifications of RNA Editing
Gerard Platenburg
Co-Founder and Chief Innovation Officer
ProQR
Day Two
Wednesday April 6, 2022
11:00 am | Understanding Lessons Learned From AON Clinical Development and Translation to the RNA Base Editing Axiomer Technology
Venkat Krishnamurthy
Executive Director
Eli Lilly
Day One
Tuesday April 5, 2022
4:00 pm | Chair’s Closing Remarks
8:30 am | Chair’s Opening Remarks
Anja Mølhart Høg
Technology Officer, RNA Therapeutics
Roche
Wensheng Wei
Scientific Founder, EdiGene, Professor with tenure and Director
Peking University Genome Editing Research Center
Day One
Tuesday April 5, 2022
1:10 pm | Leaper 2.0: Next Generation of Leveraging Endogenous ADAR for Programmable Editing on RNA
Paul Bolno, MD
President and Chief Executive Officer
Wave Life Sciences
Day Two
Wednesday April 6, 2022
4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing
Post-Conference Focus Day
Thursday April 7, 2022
11:20 am | Morning Q&A and Panel Discussion – Improving Delivery Performance
10:50 am | Unlocking Therapeutic RNA Editing
Andrew Fraley
Founder and Chief Technology Officer
Korro Bio
Day One
Tuesday April 5, 2022
11:40 am | Panel Discussion: Chemical Modifications of RNA Editing
Day Two
Wednesday April 6, 2022
5:10 pm | Chair’s Closing Remarks
8:30 am | Chair’s Opening Remarks
Adrian Briggs
Head of Platform Technologies
Shape Therapeutics
Day One
Tuesday April 5, 2022
9:40 am | RNAfix: Therapeutic RNA Editing with Engineered Guide RNAs and Endogenous ADAR
David J. Huss, PhD
Chief Scientific Officer
Shape Therapeutics
Post-Conference Focus Day
Thursday April 7, 2022
11:20 am | Morning Q&A and Panel Discussion – Improving Delivery Performance
10:20 am | Delivery Considerations for RNA Editing Payloads
Paloma Giangrande
Vice President, Platform Discovery Sciences, Biology
Wave Life Sciences
Day Two
Wednesday April 6, 2022
11:30 am | AIMers: Correcting Driver Mutations for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) and Beyond
Dinah Weismann
Chief Executive Officer & Chief Scientific Officer
Alcediag
Day Two
Wednesday April 6, 2022
4:40 pm | Panel Discussion: The Future Possibilities of RNA Editing
1:00 pm | RNA Editing for Personalized Diagnostics in Neuropsychiatry
Chandra Vargeese, PhD
Chief Technology Officer
Wave Life Sciences
Day One
Tuesday April 5, 2022
11:40 am | Panel Discussion: Chemical Modifications of RNA Editing
Massimiliano Clamer
President & Founder
Immagina Biotechnology
Day One
Tuesday April 5, 2022
2:45 pm | ITN-European Union ROPES Network
Sophia Shamsi
Research Analyst for RNA Editing
Beacon
Day Two
Wednesday April 6, 2022